| pubmed-article:16126619 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16126619 | lifeskim:mentions | umls-concept:C0032148 | lld:lifeskim |
| pubmed-article:16126619 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:16126619 | lifeskim:mentions | umls-concept:C0678793 | lld:lifeskim |
| pubmed-article:16126619 | lifeskim:mentions | umls-concept:C0086930 | lld:lifeskim |
| pubmed-article:16126619 | lifeskim:mentions | umls-concept:C0052432 | lld:lifeskim |
| pubmed-article:16126619 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:16126619 | pubmed:dateCreated | 2005-8-29 | lld:pubmed |
| pubmed-article:16126619 | pubmed:abstractText | Artesunate (AS) is being developed as a potential agent for the treatment of severe and complicated malaria. A risk assessment of the therapeutic index and related hematological changes of AS and artelinate (AL) following daily intravenous injection for 3 days was conducted in Plasmodium berghei-infected and uninfected rats. The minimum doses of AS and AL for parasitemia suppression were 2.3 and 2.5 mg/kg, respectively, and the suppressive doses for half parasitemia (SD50) were 7.4 and 8.6 mg/kg, respectively. The maximum tolerated dose (MTD) for AS was 240 mg/kg with a therapeutic index of 32.6. The MTD for AL was 80 mg/kg with a therapeutic index of 9.3. Hematological changes were studied on days 1 and 8 after the final dosing. In both AS- and AL-treated rats, dose-dependent and rapidly reversible hematological changes (significant reductions in RBC, HCT, Hb, and reticulocyte levels) were seen in the peripheral blood. Bone marrow evaluation revealed a statistically significant reduction in the myeloid/erythroid ratio only at the highest dose of AS (240 mg/kg), albeit still within the normal ratio range (1.0-1.5:1.0). Looking at the respective therapeutic indices the authors have concluded that AS is much safer than AL. Both drugs induced hematological changes in rats that parallel the dose-dependent, reversible anemia and reticulocytopenia previously reported in animals and humans. However, no significant bone marrow depression was seen for either agent. | lld:pubmed |
| pubmed-article:16126619 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16126619 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16126619 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16126619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16126619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16126619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16126619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16126619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16126619 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16126619 | pubmed:issn | 1091-5818 | lld:pubmed |
| pubmed-article:16126619 | pubmed:author | pubmed-author:LisinaO ROR | lld:pubmed |
| pubmed-article:16126619 | pubmed:author | pubmed-author:WeinaPeter... | lld:pubmed |
| pubmed-article:16126619 | pubmed:author | pubmed-author:JohnsonTodd... | lld:pubmed |
| pubmed-article:16126619 | pubmed:author | pubmed-author:WongElaineE | lld:pubmed |
| pubmed-article:16126619 | pubmed:author | pubmed-author:LiQiguiQ | lld:pubmed |
| pubmed-article:16126619 | pubmed:author | pubmed-author:SiYuanzhengY | lld:pubmed |
| pubmed-article:16126619 | pubmed:author | pubmed-author:UpadhyayRaviR | lld:pubmed |
| pubmed-article:16126619 | pubmed:author | pubmed-author:HaeberleAdamA | lld:pubmed |
| pubmed-article:16126619 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16126619 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:16126619 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16126619 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16126619 | pubmed:pagination | 251-64 | lld:pubmed |
| pubmed-article:16126619 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:meshHeading | pubmed-meshheading:16126619... | lld:pubmed |
| pubmed-article:16126619 | pubmed:articleTitle | Risk assessment and therapeutic indices of artesunate and artelinate in Plasmodium berghei-infected and uninfected rats. | lld:pubmed |
| pubmed-article:16126619 | pubmed:affiliation | Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20307-5100, USA. | lld:pubmed |
| pubmed-article:16126619 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16126619 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:16126619 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
